News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Results>JACOBIO PHARMA (02617.HK) Annual Loss Expands to RMB296 Million
JACOBIO PHARMA-B (02617.HK) announced its 2025 annual results, reporting a loss of RMB296 million (same below), compared to a loss of RMB275 million in the previous year; the loss ...
Reset
Send
The window will close in 5 seconds
<Results>JACOBIO PHARMA (02617.HK) Annual Loss Expands to RMB296 Million
Close
Recommend
1
Positive
2
Negative
2
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

JACOBIO PHARMA-B (02617.HK)  +0.850 (+1.227%)    Short selling $2.26M; Ratio 9.351%   announced its 2025 annual results, reporting a loss of RMB296 million (same below), compared to a loss of RMB275 million in the previous year; the loss per share was RMB0.76. No dividend was declared. No revenue was generated during the year. (de/d)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-02 16:25.)

Dividend History
Announce DateEventParticular
2025/08/25InterimNo Dividend



This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

Auto-translated by AI
View Original Text

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.